Eli Lilly and Company officially expanded its immunology pipeline and advanced therapeutic portfolio through the acquisition of Dermira, which was announced in January 2020 and successfully completed in February 2020. This multi-billion-dollar all-cash transaction valued at approximately $1.1 billion secured full global rights to lebrikizumab, an innovative late-stage monoclonal antibody designed to target interleukin-13 for the treatment of moderate-to-severe atopic dermatitis, alongside acquiring the topical anticholinergic treatment Qbrexza.